论文部分内容阅读
目的:探讨丙酸氟替卡松联合无创正压通气急诊治疗COPD的临床效果。方法:以我院在2014年6月到2015年1月收治的80例COPD患者作为研究对象,将其随机分为对照组和观察组,各40例,对照组患者采用丙酸氟替卡松治疗,观察组患者采用丙酸氟替卡松联合无创正压通气治疗,并比较两组患者的治疗效果。结果:经过治疗,观察组的患者总有效率显著高于对照组(100%vs 80%,P<0.05)。观察组患者PEF明显高于对照组[(7.94±0.46)ml·s~(-1) vs(7.50±0.68)ml·s~(-1),P<0.05]。另外,观察组患者FEV1、FEF25-75明显优于对照组(P<0.05)。结论:临床上在治疗COPD时,可以采用丙酸氟替卡松联合无创正压通气治疗的方法,能有效提高疾病的治疗效果,值得在临床上大力推广。
Objective: To investigate the clinical effect of fluticasone propionate combined with non-invasive positive pressure ventilation in the treatment of COPD. Methods: Eighty COPD patients admitted from June 2014 to January 2015 in our hospital were randomly divided into control group (40 cases) and observation group (40 cases). Patients in the control group were treated with fluticasone propionate The patients were treated with fluticasone propionate plus noninvasive positive pressure ventilation, and the treatment effect was compared between the two groups. Results: After treatment, the total effective rate in the observation group was significantly higher than that in the control group (100% vs 80%, P <0.05). PEF in the observation group was significantly higher than that in the control group [(7.94 ± 0.46) ml · s -1 vs 7.50 ± 0.68 ml · s -1, P 0.05]. In addition, the observation group FEV1, FEF25-75 was significantly better than the control group (P <0.05). Conclusion: In clinical treatment of COPD, fluticasone propionate combined with noninvasive positive pressure ventilation can effectively improve the therapeutic effect of the disease, which is worth to be popularized clinically.